Page last updated: 2024-12-06

1,3,7,9-tetramethyluric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,3,7,9-Tetramethyluric acid is a **synthetic analog** of uric acid, a naturally occurring compound found in humans and other animals. Here's a breakdown of its features and relevance in research:

**Structure and Properties:**

* **Uric Acid Analog:** It has a similar structure to uric acid, but with four methyl groups (-CH3) attached to specific positions on the molecule.
* **Increased Stability:** The addition of methyl groups enhances its chemical stability, making it less prone to degradation compared to regular uric acid.
* **Solubility:** It exhibits a higher solubility in organic solvents than uric acid.

**Importance in Research:**

1. **Uric Acid Analog for Studies:** Because of its stability and solubility, it serves as a valuable tool for studying:
* **Metabolic Pathways:** It can be used to investigate the metabolic pathways involved in the breakdown and synthesis of uric acid.
* **Enzyme Interactions:** Researchers can use it to probe the interactions between uric acid and enzymes like xanthine oxidase.
* **Uric Acid-Related Diseases:** Its properties can be exploited to examine the role of uric acid in conditions like gout and kidney stones.

2. **Potential Therapeutic Applications:**
* **Antioxidant Activity:** Tetramethyluric acid has demonstrated antioxidant properties in some studies. Its potential as a therapeutic agent for conditions associated with oxidative stress is being investigated.
* **Anti-Inflammatory Activity:** Preliminary research suggests that it might possess anti-inflammatory effects.

3. **Analytical Chemistry:**
* **Calibration Standards:** Its stability and purity make it suitable as a calibration standard for analytical techniques used to measure uric acid levels.

**In summary, 1,3,7,9-tetramethyluric acid is a synthetic analog of uric acid with unique properties that make it a valuable tool for research in areas like metabolism, enzyme interactions, drug development, and analytical chemistry.**

**Note:** While research on 1,3,7,9-tetramethyluric acid is ongoing, its full potential as a therapeutic agent or research tool is still being explored.

1,3,7,9-tetramethyluric acid: RN from CHEMID [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,3,7,9-tetramethyluric acid : An oxopurine that is uric acid in which the hydrogens at positions 1,3,7 and 9 are replaced by methyl groups. It is a purine alkaloid that is found in Chinese tea known as kucha (Camellia assamica var. kucha) and exhibits anti-inflammatory and analgesic properties. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID75324
CHEMBL ID143715
CHEBI ID139388
SCHEMBL ID2817943
MeSH IDM0207075

Synonyms (52)

Synonym
tetramethyl uric acid
1,3,7,9-tetramethyluric acid
tetramethyluric acid
2309-49-1
temurin
mls002638067 ,
1,7,9-tetramethyluric acid
nsc-8809
temorine
ba 2750
nsc8809
1h-purine-2,8(3h)-trione, 7,9-dihydro-1,3,7,9-tetramethyl-
uric acid,3,7,9-tetramethyl-
MEGXP0_001699
ACON1_000549
NCGC00168972-01
CHEBI:139388
teacrine
theacrine
1,3,7,9-tetramethyl-7,9-dihydro-1h-purine-2,6,8(3h)-trione
tetramethyl-2,3,6,7,8,9-hexahydro-1h-purine-2,6,8-trione
CHEMBL143715
smr001547560
1,3,7,9-tetramethylurate
BRD-K97243111-001-01-9
1,3,7,9-tetramethylpurine-2,6,8-trione
nsc 8809
einecs 218-994-1
1h-purine-2,6,8(3h)-trione, 7,9-dihydro-1,3,7,9-tetramethyl-
unii-ej939l81my
ej939l81my ,
ai3-52596
uric acid, 1,3,7,9-tetramethyl-
S11881
SCHEMBL2817943
1,3,7,9-tetramethyl-7,9-dihydro-1h-purine-2,6,8(3h)-trione #
QGDOQULISIQFHQ-UHFFFAOYSA-N
DTXSID90177659
1,3,7,9-tetramethyl-1h-purine-2,6,8(3h,7h,9h)-trione
AKOS027446341
1,3,7, 9-tetramethyluric acid
1,3,7,9-tetramethyluric acid [who-dd]
theacrin
DS-3244
FT-0749152
mfcd00042781
Q12646548
AMY36785
A924685
SY074330
1,3,7,9-tetramethyl-7,9-dihydro-3h-purine-2,6,8-trione
CS-0069995

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Primary outcomes were fasting clinical safety markers (heart rate, blood pressure, lipid profiles, hematologic blood counts, biomarkers of liver/kidney/immune function) and energy, focus, concentration, anxiety, motivation to exercise, and POMS measured prior to daily dosing to ascertain potential tachyphylactic responses and habituation effects."( Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use.
Hayward, S; Mullins, J; Mumford, P; Roberts, M; Taylor, L; Urbina, S; Wilborn, C, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (3 Product(s))

Product Categories

Product CategoryProducts
Active Lifestyle & Fitness3

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Animal Pre Workout Primal Powder Fruit Punch -- 17.9 ozAnimalActive Lifestyle & FitnessTheacrine, Beta-Alanine, Betaine Anhydrous, Caffeine Anhydrous, Choline, Calcium Carbonate, Sodium Bicarbonate, L-Taurine2024-11-29 10:47:42
Animal Pre Workout Primal Powder Strawberry Watermelon -- 17.9 ozAnimalActive Lifestyle & FitnessTheacrine, Beta-Alanine, Betaine Anhydrous, Caffeine Anhydrous, Choline, Calcium Carbonate, Sodium Bicarbonate, L-Taurine2024-11-29 10:47:42
Nutrex Research Hemo-Rage Unleashed Fruit Punch -- 30 ServingsNutrex ResearchActive Lifestyle & FitnessTheacrine, citric acid, acesulfame potassium, acesulfame potassium, Betaine Anhydrous, Caffeine Anhydrous, citric acid, Alpha GPC, malic acid, N-Acetyl-L-Tyrosine, Taurine, sucralose2024-11-29 10:47:42

Roles (4)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
analgesicAn agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
oxopurine
purine alkaloid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
caffeine degradation II04
caffeine degradation II05

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID55471Binding affinity to DNA intercalator Acridine orange.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Structural basis for the binding affinity of xanthines with the DNA intercalator acridine orange.
AID453747Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation by continuous spectrophotometric assay in presence of 10 mM L-glutamine and 0.15 mM 2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID453744Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation by continuous spectrophotometric assay in presence of 150 mM NH4Cl2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID28659Ability to solubilize benzo(a)pyrene in water was reported by Weil-Malherbe.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Structural basis for the binding affinity of xanthines with the DNA intercalator acridine orange.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (2.78)18.2507
2000's4 (11.11)29.6817
2010's16 (44.44)24.3611
2020's15 (41.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.06 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index5.50 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (13.89%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (86.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]